155 related articles for article (PubMed ID: 2522806)
1. HLA-DR expression by high grade superficial bladder cancer treated with BCG.
Prescott S; James K; Busuttil A; Hargreave TB; Chisholm GD; Smyth JF
Br J Urol; 1989 Mar; 63(3):264-9. PubMed ID: 2522806
[TBL] [Abstract][Full Text] [Related]
2. Local immune responses after intravesical BCG treatment for carcinoma in situ.
el-Demiry MI; Smith G; Ritchie AW; James K; Cumming JA; Hargreave TB; Chisholm GD
Br J Urol; 1987 Dec; 60(6):543-8. PubMed ID: 3501324
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.
Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
J Urol; 1992 Jun; 147(6):1636-42. PubMed ID: 1593713
[TBL] [Abstract][Full Text] [Related]
4. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
5. Immunopathological effects of intravesical BCG therapy.
Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
Prog Clin Biol Res; 1989; 310():93-105. PubMed ID: 2672025
[No Abstract] [Full Text] [Related]
6. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
9. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
10. Reactive arthritis associated with Bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: a report of two cases.
Jawad AS; Kahn L; Copland RF; Henderson DC; Abdul-Ahad AK
Br J Rheumatol; 1993 Nov; 32(11):1018-20. PubMed ID: 8220923
[No Abstract] [Full Text] [Related]
11. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
12. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
14. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.
Jurincic-Winkler C; Metz KA; Beuth J; Engelmann U; Klippel KF
Br J Urol; 1995 Dec; 76(6):702-7. PubMed ID: 8535712
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
[TBL] [Abstract][Full Text] [Related]
16. Intravesical BCG therapy in patients with superficial bladder tumors.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
[No Abstract] [Full Text] [Related]
17. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
18. Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells.
Hermann GG; Petersen KR; Zeuthen J; Steven K
Scand J Urol Nephrol; 1991; 25(4):269-73. PubMed ID: 1780700
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin.
Brenner DW; Yore LM; Schellhammer PF
Urology; 1989 Aug; 34(2):93-5. PubMed ID: 2763404
[TBL] [Abstract][Full Text] [Related]
20. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]